Maven Securities’s Viking Therapeutics VKTX Stock Holding History

Maven Securities’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200,000	Closed	-$3.33M	–	1065
2023 Q1	$3.33M	Buy	+200,000	New	+$2.07M	0.07%	194

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Maven Securities's VKTX Position: Q2 2023 in Review

Maven Securities sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 200,000 shares — an estimated $3.33M sold.

Maven Securities first reported a position in VKTX in Q1 2023 and held it in 1 quarter. The position peaked at $3.33M in Q1 2023. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

Maven Securities reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
Maven Securities sold 200,000 Viking Therapeutics shares in Q2 2023, an estimated $3.33M.
Maven Securities first reported a position in Viking Therapeutics in Q1 2023 and held it in 1 quarter.
Maven Securities's Viking Therapeutics position peaked at $3.33M in Q1 2023.
193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Maven Securities's 13F filing for Q2 2023, filed 4 Aug 2023.